Hetero ‘Global Access’ is a business vertical dedicated to managing the supply of quality medicines to renowned global procurement bodies. We have legacy of treating HIV/AIDS since 1997, making us one of the global leaders in production and supply of affordable ARV APIs and Formulations. About 30+ of our ARV combinations cater to ~40%* of identified HIV/AIDS patients’ treatment worldwide.
Launched the world’s first-ever fixed dosage combinations such as Darunavir + Ritonavir and Emtricitabine + Tenofovir Alafenamide, underscoring our expertise in ARVs
Among the first in India and around the world to introduce a portfolio of life-saving hepatitis drugs such as Sofosbuvir and fixed-dose combination therapies through global licensing agreements
*Ref: Either API or FDF. Data on file
Countries where our products are marketed
Product registrations with local regulatory authorities
ARV drugs in portfolio